Probucol, sold under the trade name Lorelco among others, is an lipid-lowering agent initially developed for the treatment of coronary artery disease. It is a highly lipophilic bisphenolic antioxidant that lowers plasma low density lipoprotein cholesterol through enhanced LDL catabolism and inhibition of oxidative modification of lipoproteins, with a characteristic effect of lowering high density lipoprotein cholesterol as well. Chemically, probucol contains thioether linkages that are susceptible to oxidative transformation, and most quality control testing relies on reversed-phase HPLC with UV detection, supported by LC-MS for related substances and GC for residual solvents. Typical formulation uses include oral solid dosage forms; pharmacokinetics show extensive tissue distribution and slow elimination consistent with high lipophilicity. Clinical and preclinical studies have explored probucol for atherosclerotic plaque stabilization and prevention of restenosis due to its antioxidant and antiinflammatory properties.
Probucol technical specifications and impurity control focus on oxidative and dealkylation products, sulfoxide and sulfone oxidation products of the thioether moiety, dealkylated or de-tert-butylated phenolic derivatives, and low-level polymeric or dimeric oxidative products. Typical analytical acceptance criteria used by manufacturers and compendial-style specifications are: assay by HPLC 98.0 to 102.0 percent of label claim; individual related compounds not more than 0.2 percent each; specified impurities such as sulfoxide and sulfone combined not more than 0.5 percent; total related substances not more than 1.0 percent; unspecified impurity reporting threshold set at 0.05 to 0.10 percent depending on intended daily dose; residual solvents controlled to ICH Q3C class limits; and elemental impurities limited in line with ICH Q3D, commonly with individual heavy metals below 10 ppm. Identification of major related compounds is performed by LC-MS and confirmed by reference standards when available, and stability studies monitor increase in oxidative and dealkylation impurities under forced degradation conditions.
Probucol is used as a lipid-lowering agent primarily to reduce low density lipoprotein cholesterol and to exert antioxidant protection against lipoprotein oxidation; it was developed for coronary artery disease and has been used in some countries for hypercholesterolemia and for investigational indications such as restenosis prevention.
No, Probucol is not approved by the United States Food and Drug Administration for routine clinical use; it has been marketed in some other countries under various trade names, and its regulatory status varies by region and by the particular product formulation.
No, Probucol is not a statin. Statins are HMG-CoA reductase inhibitors that lower cholesterol synthesis; probucol is a lipophilic antioxidant that lowers plasma cholesterol primarily by enhancing LDL clearance and by preventing oxidative modification of lipoproteins.
Common and clinically significant adverse effects include reduction of high density lipoprotein cholesterol, gastrointestinal disturbances such as nausea, and dermatologic reactions; important safety concerns include QT interval prolongation with a risk of ventricular arrhythmia, and potential hepatic enzyme changes, so ECG and liver function monitoring are recommended in patients receiving the drug.
